nach oben

BioDrugs

Erschienen in:

01.03.2005 | Molecular Diagnostics

Usefulness of the Novel Oncofetal Antigen Glypican-3 for Diagnosis of Hepatocellular Carcinoma and Melanoma

verfasst von: Dr Tetsuya Nakatsura, Yasuharu Nishimura

Erschienen in: BioDrugs | Ausgabe 2/2005

Einloggen, um Zugang zu erhalten

Abstract

Glypican-3 (GPC3) mRNA and protein are expressed in >80% of human hepatocellular carcinomas (HCC) but not in normal tissues except for placenta and fetal liver. The oncofetal antigen GPC3 is a glycosylphosphatidyl inositol-anchored membrane protein and may be secreted. It is a novel tumor marker for human HCC: GPC3 protein was present in sera from 40–50% of HCC patients, but was not detected in sera from patients with liver cirrhosis or chronic hepatitis, or in sera from healthy individuals. α-Fetoprotein (AFP) and PIVKA-II (protein induced by vitamin K absence or antagonist-II), are well known major tumor markers for HCC. Generally, AFP shows high positivity for HCC but also high false-positivity in detection assays. Lens culinaris agglutinin-reactive fraction of α-fetoprotein (AFP-L3) is a recently described marker of HCC. Detection of AFP-L3 shows a much higher specificity than AFP, but a lower sensitivity. On the other hand, detection of PIVKA-II shows a lower false-positivity, but is not always sensitive enough to detect low levels secreted by small HCCs. There was no correlation between the three tumor markers, AFP, PIVKA-II, and GPC3 in terms of their presence in HCC cells. All three tumor markers showed similar positivity in patients with HCC, detecting 80% of patients with the disease.

GPC3 is also a novel tumor marker for the diagnosis of human melanoma, especially in the early stages of the disease. Expression of GPC3 mRNA and protein was evident in tumor cells from >80% of patients with melanoma and melanocytic nevus, which is a common benign lesion. GPC3 protein was detected in sera from 40% (36/91) of melanoma patients, but not in sera from those with large congenital melanocytic nevus, or from healthy donors. Surprisingly, we detected serum GPC3 even in patients with stage 0, in situ melanoma. The positive detection rate of serum GPC3 at stage 0,1, and II (44.4%, 40.0%, 47.6%, respectively) was significantly higher than that of 5-S-cysteinyldopa, a well known tumor marker for melanoma (0.0%, 8.0%, and 10.0%, respectively).

Interestingly, GPC3 was highly immunogenic in mice and elicited effective anti-tumor immunity with no evidence of autoimmunity. Thus, GPC3 is useful for diagnosis of HCC and melanoma and may also have a role in immunotherapy or tumor prevention. However, studies in humans are warranted.

Di Bisceglie AM. Issues in screening and surveillance for hepatocellular carcinoma. Gastroenterology 2004; 127(5 Suppl. 1): S104–7PubMedCrossRef

Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet 1999; 353: 1253–7PubMedCrossRef

Guadagni F, Ferroni P, Carlini S, et al. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. Clin Cancer Res 2001; 7: 2357–62PubMed

Maehara Y, Sugimachi K, Akagi M, et al. Serum carcinoembryonic antigen level increases correlate with tumor progression in patients with differentiated gastric carcinoma following noncurative resection. Cancer Res 1990; 50: 3952–5PubMed

Harmenberg U, Wahren B, Wiechel KL. Tumor markers carbohydrate antigens CA 19-9 and CA-50 and carcinoembryonic antigen in pancreatic cancer and benign diseases of the pancreatobiliary tract. Cancer Res 1988; 48: 1985–8PubMed

Gerl A, Lamerz R, Clemm C, et al. Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors? Clin Cancer Res 1996; 2: 1565–70PubMed

Fujiyama S, Tanaka M, Maeda S, et al. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 2002; 62Suppl. 1: 57–63PubMedCrossRef

Marks R. Epidemiology of melanoma. Clin Exp Dermatol 2000; 25(6): 459–63PubMedCrossRef

Brochez L, Naeyaert JM. Serological markers for melanoma. Br J Dermatol 2000; 143: 256–68PubMedCrossRef

10.

Hauschild A, Glaser R, Christophers E. Quantification of melanoma-associated molecules in plasma/serum of melanoma patients. Recent Results Cancer Res 2001; 158: 169–77PubMedCrossRef

11.

Hartleb J, Arndt R. Cysteine and indole derivatives as markers for malignant melanoma. J Chromatogr B Biomed sci Appl 2001; 764: 409–43PubMedCrossRef

12.

Kageshita T, Yoshii A, Kimura T, et al. Clinical relevance of ICAM-1 expression in primary lesions and serum of patients with malignant melanoma. Cancer Res 1993; 53: 4927–32PubMed

13.

Schlagenhauff B, Schittek B, Ellwanger U, et al. Significance of serum protein S100 levels in screening for melanoma metastasis: does protein S100 enable early detection of melanoma recurrence? Melanoma Res 2000; 10: 451–9PubMedCrossRef

14.

Reinhardt MJ, Kensy J, Frohmann JP, et al. Value of tumour marker S-100B in melanoma patients: a comparison to 18F-FDG PET and clinical data. Nuklearmedizin 2002; 41: 143–7PubMed

15.

Wimmer I, Meyer JC, Scifert B, et al. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy. Cancer Res 1997; 57: 5073–6PubMed

16.

Wakamatsu K, Yokochi M, Naito A, et al. Comparison of phaeomelanin and its precursor 5-S-cysteinyldopa in the serum of melanoma patients. Melanoma Res 2003; 13: 357–63PubMedCrossRef

17.

Wakamatsu K, Kageshita T, Furue M, et al. Evaluation of 5-S-cysteinyldopa as a marker of melanoma progression: 10 years’ experience. Melanoma Res 2002; 12: 245–53PubMedCrossRef

18.

Hirai S, Kageshita T, Kimura T, et al. Serum levels of sICAM-1 and 5-S-cysteinyldopa as markers of melanoma progression. Melanoma Res 1997; 7: 58–62PubMedCrossRef

19.

Bosserhoff AK, Kaufmann M, Kaluza B, et al. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 1997; 57: 3149–53PubMed

20.

Muhlbauer M, Langenbach N, Stolz W, et al. Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR. Clin Cancer Res 1999; 5: 1099–105PubMed

21.

Hanawa Y, Wakamatsu K, Ikeda S. Serum concentration of 5-S-cysteinyldopa in pediatric patients with giant pigmented nevi. J Dermatol 1996; 23: 16–21PubMed

22.

van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643–7PubMedCrossRef

23.

Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411: 380–4PubMedCrossRef

24.

Morgan RA, Dudley ME, Yu YY, et al. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol 2003; 171: 3287–95PubMed

25.

Maeda Y, Ito M, Harashima N, et al. Cleavage and polyadenylation specificity factor (CPSF)-derived peptides can induce HLA-A2-restricted and tumor-specific CTLs in the majority of gastrointestinal cancer patients. Int J Cancer 2002; 99: 409–17PubMedCrossRef

26.

Azuma K, Shichijo S, Maeda Y, et al. Mutated p53 gene encodes a nonmutated epitope recognized by HLA-B*4601-restricted and tumor cell-reactive CTLs at tumor site. Cancer Res 2003; 63: 854–8PubMed

27.

Park S, Lim Y, Lee D, et al. Identification and characterization of a novel cancer/ testis antigen gene CAGE-1. Biochim Biophys Acta 2003; 1625: 173–82PubMedCrossRef

28.

Jager E, Chen YT, Drijfhout JW, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human his-tocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998; 187: 265–70PubMedCrossRef

29.

Nakatsura T, Senju S, Yamada K, et al. Gene cloning of immunogenic antigens overexpressed in pancreatic cancer. Biochem Biophys Res Commun 2001; 281: 936–44PubMedCrossRef

30.

Nakatsura T, Senju S, Ito M, et al. Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method. Eur J Immunol 2002; 32: 826–36PubMedCrossRef

31.

Monji M, Senju S, Nakatsura T, et al. Head and neck cancer antigens recognized by the humoral immune system. Biochem Biophys Res Commun 2002; 294: 734–41PubMedCrossRef

32.

Kai M, Nakatsura T, Egami H, et al. Heat shock protein 105 is overexpressed in a variety of human tumors. Oncol Rep 2003; 10: 1777–82PubMed

33.

Monji M, Nakatsura T, Senju S, et al. Identification of a novel human cancer/testis antigen, KM-HN-1, recognized by cellular and humoral immune responses. Clin Cancer Res 2004; 10: 6047–57PubMedCrossRef

34.

Hasegawa S, Furukawa Y, Li M, et al. Genome-wide analysis of gene expression in intestinal-type gastric cancers using a complementary DNA microarray representing 23,040 genes. Cancer Res 2002; 62: 7012–7PubMed

35.

Zembutsu H, Ohnishi Y, Tsunoda T, et al. Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res 2002; 62: 518–27PubMed

36.

Kitahara O, Furukawa Y, Tanaka T, et al. Alterations of gene expression during colorectal carcinogenesis revealed by cDNA microarrays after laser-capture microdissection of tumor tissues and normal epithelia. Cancer Res 2001; 61: 3544–9PubMed

37.

Yu Y, Khan J, Khanna C, et al. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med 2004; 10: 175–81PubMedCrossRef

38.

Kitahara O, Katagiri T, Tsunoda T, et al. Classification of sensitivity or resistance of cervical cancers to ionizing radiation according to expression profiles of 62 genes selected by cDNA microarray analysis. Neoplasia 2002; 4: 295–303PubMedCrossRef

39.

Yoshitake Y, Nakatsura T, Monji M, et al. Proliferation potential-related protein, an ideal esophageal cancer antigen for immunotherapy, identified using complementary DNA microarray analysis. Clin Cancer Res 2004; 10: 6437–48PubMedCrossRef

40.

Okabe H, Satoh S, Kato T, et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 2001; 61: 2129–37PubMed

41.

Saito-Hisaminato A, Katagiri T, Kakiuchi S, et al. Genome-wide profiling of gene expression in 29 normal human tissues with a cDNA microarray. DNA Res 2002; 9: 35–45PubMedCrossRef

42.

Nakatsura T, Yoshitake Y, Senju S, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003; 306: 16–25PubMedCrossRef

43.

Hsu HC, Cheng W, Lai PL. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res 1997; 57: 5179–84PubMed

44.

Zhu ZW, Friess H, Wang L, et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 2001; 48: 558–64PubMedCrossRef

45.

Sung YK, Hwang SY, Park MK, et al. Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer sci 2003; 94: 259–62PubMedCrossRef

46.

Midorikawa Y, Ishikawa S, Iwanari H, et al. Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer 2003; 103: 455–65PubMedCrossRef

47.

Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003; 125: 89–97PubMedCrossRef

48.

Hippo Y, Watanabe K, Watanabe A, et al. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004; 64: 2418–23PubMedCrossRef

49.

Nakatsura T, Kageshita T, Ito S, et al. Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res 2004; 10: 6612–21PubMedCrossRef

50.

Nakatsura T, Komori H, Kubo T, et al. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T cell-mediated tumor rejection without autoimmune reactions in mice. Clin Cancer Res 2004; 10(24): 8630–40PubMedCrossRef

51.

Pilia G, Hughes-Benzie RM, MacKenzie A, et al. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet 1996; 12: 241–7PubMedCrossRef

52.

Neri G, Gurrieri F, Zanni G, et al. Clinical and molecular aspects of the Simpson-Golabi-Behmel syndrome. Am J Med Genet 1998; 79: 279–83PubMedCrossRef

53.

Garganta CL, Bodurtha JN. Report of another family with Simpson-Golabi-Behmel syndrome and a review of the literature. Am J Med Genet 1992; 44: 129–35PubMedCrossRef

54.

Gurrieri F, Cappa M, Neri G. Further delineation of the Simpson-Golabi-Behmel (SGB) syndrome. Am J Med Genet 1992; 44: 136–7PubMedCrossRef

55.

Hughes-Benzie RM, Pilia G, Xuan JY, et al. Simpson-Golabi-Behmel syndrome: genotype/phenotype analysis of 18 affected males from 7 unrelated families. Am J Med Genet 1996; 66: 227–34PubMedCrossRef

56.

Xuan JY, Hughes-Benzie RM, MacKenzie AE. A small interstitial deletion in the GPC3 gene causes Simpson-Golabi-Behmel syndrome in a Dutch-Canadian family. J Med Genet 1999; 36: 57–8PubMed

57.

Cano-Gauci DF, Song HH, Yang H, et al. Glypican-3-deficient mice exhibit developmental overgrowth and some of the abnormalities typical of Simpson-Golabi-Behmel syndrome. J Cell Biol 1999; 146: 255–64PubMed

58.

Gonzalez AD, Kaya M, Shi W, et al. OCI-5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell line-specific manner. J Cell Biol 1998; 141: 1407–14PubMedCrossRef

59.

Lin H, Huber R, Schlessinger D, et al. Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res 1999; 59: 807–10PubMed

Titel: Usefulness of the Novel Oncofetal Antigen Glypican-3 for Diagnosis of Hepatocellular Carcinoma and Melanoma
verfasst von: Dr Tetsuya Nakatsura
Yasuharu Nishimura
Publikationsdatum: 01.03.2005
Verlag: Springer International Publishing
Erschienen in: BioDrugs / Ausgabe 2/2005
Print ISSN: 1173-8804
Elektronische ISSN: 1179-190X
DOI: https://doi.org/10.2165/00063030-200519020-00001

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten